Trametinib generics

Trametinib(trametinib)alone or in combination with dabrafenib for the treatment of unresectable or metastatic melanoma in selected patients with BRAF V600E or V600K mutations. In combination with dabrafenib, it is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in patients with BRAF V600E mutations. In combination with dabrafenib for the treatment of locally advanced or metastatic anaplastic thyroid cancer in patients with BRAF V600E mutations when no satisfactory locoregional treatment options are available. In combination with dabrafenib, it is indicated for the treatment of adult and pediatric patients aged ≥6 years who have unresectable or metastatic solid tumors (excluding colorectal cancer) with BRAF V600E mutations that have progressed after prior therapy and for whom there are no satisfactory alternative treatments. Designated as an orphan drug by the FDA when used in combination with malignant glioma.

Trametinib was approved for marketing by the U.S. Food and Drug Administration (FDA) on May 29, 2013, and was approved for marketing by the State Food and Drug Administration of China in March 2020. The price in domestic pharmacies is 9,800 yuan for 30 tablets of 2 mg. There is an original drug in Türkiye, which is sold in pharmacies for 7,900 yuan for 30 tablets of 2 mg. The cost of original research drugs is relatively high. Trametinib has a officially marketed version in Laos and has government approval. Laos Daxiong Pharmaceutical is currently producing this medicine, and the retail price of the drug is about 3,000 yuan for 30 tablets of 2 mg. Patients can choose drug versions based on their own economic conditions. Regularly marketed generic drugs have the same ingredients and specifications as the original drugs. If you want to get more high-quality information, you can contact Yaode, and Yaode will do its best to learn more about high-quality overseas drugs for you.

xa0

xa0